FamiCord AG (formerly VITA 34 AG) — Cyborg Score 7/10
Solid
Medical Technology / Cell Banking & Regenerative Medicine
Strategic Profile
The company completed group-wide integration projects following the merger of Vita 34 and PBKM subgroups and recently rebranded to FamiCord AG to strengthen international brand presence. The company is active in the areas of Cell & Gene therapies and CDMO (contract development and manufacturing organization). The strategic positioning emphasizes European market dominance with controlled expansion into adjacent cell therapy applications.
Cyborg Score Rationale
Revenues increased by 6.6 percent to EUR 82.2 million in 2024 and EBITDA grew to EUR 8.8 million despite increased investments in marketing and sales. The company maintains solid cash reserves and demonstrates profitable operations in a growing cell banking market, though faces competitive pressures in domestic German market.
Top Insights
Customers from about 50 countries have already provided for the health of their families with about one million units of stored biological material at FamiCord.
In the 2024 financial year, the company successfully continued its growth trajectory with revenues increasing 6.6% to EUR 82.2 million and EBITDA reaching EUR 8.8 million.
Recent rebranding to FamiCord AG completed post-merger integration and strengthened international brand presence following the merger of Vita 34 and PBKM subgroups.
FamiCord continued the roll-out of its placenta banking service in the fourth quarter of 2024.
Named Competitors
Cord Blood Banking — European private cord blood banking competitor
Cord Blood Banking — Global cord blood banking and storage services
Cell Therapy Solutions — Public cord blood banking networks across Europe
Recent Developments
(April 2025) FamiCord AG rebranded from VITA 34 AG to strengthen international presence; completed post-merger integration
(April 2025) 2024 results: EUR 82.2M revenue (+6.6% YoY), EUR 8.8M EBITDA with continued placenta banking expansion
(August 2024) Thomas Pfaadt appointed as Chief Financial Officer
Open the full interactive FamiCord AG (formerly VITA 34 AG) report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.